Lab Med and Pathology Research & Discovery Seminar: Matt Kaeberlein - Toward clinical evaluation of rapamycin to target biological aging

Toward clinical evaluation of rapamycin to target biological aging

Matt Kaeberlein, PhD

Professor, Director, Healthy Aging & Longevity Research Institute
Director, Nathan Shock Center of Excellence in The Basic Biology of Aging
Director, Biological Mechanisms of Healthy Aging Training Program
Co-Director, Dog Aging Project
Department of Laboratory Medicine & Pathology
University of Washington

Why Attend this Seminar?
The mTOR inhibitor rapamycin is the most robust and reproducible pharmacological intervention to increase lifespan and healthspan metrics in laboratory animals. Several groups have independently shown that short-term treatment with rapamycin during middle-age in mice can prevent age-related decline or rejuvenate functional measures of health in various organs and tissues including brain, heart, kidney, muscle, oral cavity, immune system, and ovary. Here I will summarize the preclinical evidence that rapamycin can positively modulate biological aging and describe current efforts to determine whether these effects are shared in companion dogs and people.

Chapters:
0:00 - Introduction by Dr. Alexander Mendenhall
1:01 - Dr. Kaeberlein's Presentation
59:30 - Q&A